...
首页> 外文期刊>Archives of Toxicology >Kinetic interactions of a neuropathy potentiator (phenylmethylsulfonyl fluoride) with the neuropathy target esterase and other membrane bound esterases
【24h】

Kinetic interactions of a neuropathy potentiator (phenylmethylsulfonyl fluoride) with the neuropathy target esterase and other membrane bound esterases

机译:神经病增强剂(苯基甲基磺酰氟)与神经病靶标酯酶和其他膜结合酯酶的动力学相互作用

获取原文
获取原文并翻译 | 示例
           

摘要

Phenylmethylsulfonyl fluoride (PMSF) is a protease and esterase inhibitor that causes protection, or potentiation/"promotion," of organophosphorus delayed neuropathy (OPIDN), depending on whether it is dosed before or after an inducer of delayed neuropathy, such as mipafox. The molecular target of the potentiation/promotion of OPIDN has not yet been identified. The kinetic data of phenyl valerate esterase inhibition by PMSF were obtained with membrane chicken brain fractions, the animal model and tissue in which neuropathy target esterase (NTE) was first described. Data were analyzed using a kinetic model with a multienzymatic system in which inhibition, simultaneous chemical hydrolysis of the inhibitor and "ongoing inhibition" (inhibition during the substrate reaction) were considered. Three main esterase components were discriminated: two sensitive enzymatic entities representing 44 and 41 %, with I 50 (20 min) of 35 and 198 μM at 37 C, respectively, and a resistant fraction of 15 % of activity. The estimated constant of the chemical hydrolysis of PMSF was also calculated (kh = 0.28 min-1). Four esterase components were globally identified considering also previously data with paraoxon and mipafox: EPα (4-8 %), highly sensitive to paraoxon and mipafox, spontaneously reactivates after inhibition with paraoxon, and resistant to PMSF; EPβ (38-41 %), sensitive to paraoxon and PMSF, but practically resistant to mipafox, this esterase component has the kinetic characteristics expected for the PMSF potentiator target, even though paraoxon cannot be a potentiator in vivo due to high AChE inhibition; EPγ (NTE) (39-48 %), paraoxon-resistant and sensitive to the micromolar concentration of mipafox and PMSF; and EPδ (10 %), resistant to all the inhibitors assayed. This kinetic characterization study is needed for further isolation and molecular characterization studies, and these PMSF phenyl valerate esterase components will have to be considered in further studies of OPIDN promotion. A simple test for monitoring the four esterase components is proposed.
机译:苯甲基磺酰氟(PMSF)是一种蛋白酶和酯酶抑制剂,可引起有机磷延迟神经病(OPIDN)的保护或增强/“促进”,具体取决于它是在延迟神经病的诱发剂(如mipafox)之前或之后给药。尚未确定OPIDN增强/促进的分子靶标。用膜鸡脑部分,动物模型和组织(其中首次描述了神经病靶标酯酶(NTE))获得了PMSF抑制戊酸苯基酯酶的动力学数据。使用具有多酶系统的动力学模型分析数据,其中考虑了抑制,抑制剂的同时化学水解和“进行中的抑制”(底物反应期间的抑制)。区分了三个主要的酯酶成分:两个敏感的酶实体,分别占44%和41%,在50℃(37分钟)下的I 50(20分钟)分别为35和198μM,抗性部分为活性的15%。还计算了PMSF化学水解的估计常数(kh = 0.28 min-1)。考虑到以前的对氧磷和mipafox数据,目前已确定了四种酯酶成分:EPα(4-8%),对氧磷和mipafox高度敏感,在被对氧磷抑制后自发重新活化,并且对PMSF耐药。 EPβ(38-41%)对对氧磷和PMSF敏感,但实际上对mipafox耐药,尽管对氧磷对乙酰胆碱酯酶有很高的抑制作用,但对氧磷不能成为体内的增效剂,但该酯酶组分具有预期的对PMSF增效剂靶的动力学特性。 EPγ(NTE)(39-48%),耐对氧磷,对mipafox和PMSF的微摩尔浓度敏感;和EPδ(10%),对所有测定的抑制剂均具有抗性。进行进一步的分离和分子表征研究需要此动力学表征研究,而在OPIDN促进的进一步研究中必须考虑这些PMSF苯基戊酸酯酯酶组分。提出了监测四个酯酶成分的简单测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号